Serum Oncostatin M in Ulcerative Colitis Patients and Its Relation to Disease Activity
Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease; non-invasive biomarkers that accurately reflect the endoscopic and histological activity of UC require validation. Therefore, our study focused on exploring the potential of serum oncostatin M (OSM) as a biomarker for evaluating UC severity. A total of UC 89 eligible participants (≥18 years) underwent extensive clinical and paraclinical evaluation. Clinical, endoscopic, and histological activity were assessed using the partial Mayo score (pMS), the Mayo endoscopic score (MES), and the Nancy Histological Index (NHI), respectively. Serum OSM levels were determined by ELISA test and measured in pg/mL; fecal calprotectin (FC) was measured in µ/g. In our study, serum OSM was significantly associated with all four outcome measures: higher OSM levels predicted higher pMS (β = 0.471, <i>p</i> < 0.001, R<sup>2</sup> = 0.222), MES (β = 0.422, <i>p</i> < 0.001, R<sup>2</sup> = 0.178), NHI (β = 0.422, <i>p</i> < 0.001, R<sup>2</sup> = 0.256), and FC (β = 0.431, <i>p</i> < 0.001, R<sup>2</sup> = 0.186). Furthermore, ROC curve analyses demonstrated that OSM had excellent diagnostic accuracy for active disease, particularly in relation to histological inflammation (AUC = 0.967). In comparison, FC showed good but slightly lower accuracy (AUC = 0.875). Notably, OSM also outperformed FC in discriminating histological remission. Pairwise ROC curve analyses using DeLong's test further confirmed the diagnostic accuracy of OSM, FC, and combined biomarker scores (OSM+FC) across clinical, endoscopic, and histological endpoints. The combined score PRE1 (OSM + FC based on NHI) achieved perfect discrimination (AUC = 1.000, <i>p</i> < 0.001). Composite models PRE2 and PRE3 (OSM+FC based on MES and pMS) improved diagnostic accuracy relative to OSM, confirming the value of combining OSM with FC. Although both outperformed OSM (<i>p</i> < 0.05), neither achieved a superior advantage over FC. Serum OSM is strongly associated with histological activity in UC and demonstrates superior performance compared with FC in assessing histological remission.
Authors
- Vasile-Claudiu Mihai (ORCID: https://orcid.org/0009-0003-6226-2196)
- Vasile Drug (ORCID: https://orcid.org/0000-0002-7596-2656)
- Alina Ecaterina Jucan (ORCID: https://orcid.org/0000-0003-1694-3970)
- Mihai Danciu (ORCID: https://orcid.org/0000-0002-0194-7832)
- Mariana Pavel-Tanasă (ORCID: https://orcid.org/0000-0002-2802-5993)
- Diana Gabriela Iosep (ORCID: https://orcid.org/0009-0009-3487-9299)
- Ioana-Ruxandra Mihai
- Smaranda Diaconescu (ORCID: https://orcid.org/0000-0001-8018-7191)
- Cristina Cijevschi Prelipcean (ORCID: https://orcid.org/0000-0003-4589-5584)
- Mihaela Dranga (ORCID: https://orcid.org/0000-0001-7750-6278)
- Georgiana-Emmanuela Gîlcă-Blanariu (ORCID: https://orcid.org/0000-0002-5590-6462)
- Otilia Nedelciuc
- Simona Juncu (ORCID: https://orcid.org/0009-0001-5001-4852)
- Daniela Constantinescu (ORCID: https://orcid.org/0000-0003-0732-3745)
- Cătălina Mihai
- Elena Toader
- Georgiana-Elena Sarbu
- Carmen Atodiresei
- Andrei Mihai Andronic
Institutions
- Titu Maiorescu University (RO)
- Clinical Emergency Hospital Bucharest (RO)
- Grigore T. Popa University of Medicine and Pharmacy (RO)
- Spitalul Clinic Judeţean de Urgenţe "Sf. Spiridon" Iaşi (RO)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2025-12-27
- DOI
- https://doi.org/10.3390/ijms27010307
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universitatea de Medicina și Farmacie Grigore T. Popa - Iasi